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We have recently demonstrated that neonatal astrocytes derived from mice lacking beta-2 adrenergic receptors 
(β2AR) possess higher proliferation rates, as compared to wild-type cells, an attribute that was shown to involve 
insulin-like growth factor (IGF) signaling. In the present study, we demonstrate that basal cAMP levels in β2AR 
knockout astrocytes were significantly lower than in wild type cells. Furthermore, treatment with IGF-1 reduced 
intracellular cAMP levels in wild type astrocytes, yet had no effects on cAMP levels in β2AR deficient astrocytes. 
Our data suggests that IGF-1 treatment influences cAMP production through a β2AR-dependant mechanism in 
astrocytes. A deficit of β2AR on astrocytes, as previously reported in multiple sclerosis, may influence cell pro-
liferation, an action which could have implications in processes involved in astrogliosis. 
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Introduction 
Beta-adrenergic receptors (βARs) are members of 
the superfamily of G-protein coupled receptors 
(GPCRs) and involved in fundamental processes such 
as cell growth, differentiation, and metabolism. They 
are stimulated by catecholamines, epinephrine and 
norepinephrine (NE) and play important roles in car-
diovascular, respiratory, metabolic, reproductive and 
central nervous system (CNS) functions [1]. One of the 
major cellular signaling pathways of the βARs is me-
diated by the G-protein Gsα leading to activation of 
adenylyl cyclase and increases in the second messen-
ger cyclic adenosine monophosphate (cAMP), an acti-
vator of cAMP-dependent protein kinase A (PKA).  
The type 1 insulin-like growth factor receptor 
(IGF-1R) is activated by its ligands, insulin-like growth 
factor-1 and -2 (IGF-1 and -2), which results in intrinsic 
tyrosine kinase receptor activity and the transduction 
of intracellular signaling pathways, including MAPK 
a n d  P I 3 K  p a t h w a y s  [ 2 ] .  I t  i s  b e c o m i n g  e v i d e n t  t h a t  
signaling pathways induced by receptor tyrosine 
kinases (RTK) may interact with GPCR pathways at a 
variety of intracellular levels, including direct recep-
tor-receptor interactions [3,4]. For example, insulin and 
IGF-1 have been shown to stimulate insulin and type 1 
IGF receptor-catalyzed phosphorylation of the β2AR, 
which has been shown to result in loss of receptor 
function and its activation of adenylyl cyclase [5,6].  
Multiple sclerosis (MS) is an inflammatory de-
myelinating disease of the CNS characterized by infil-
tration of macrophages and T-cells into brain paren-
chyma. This is accompanied by cytokine and 
chemokine expression and release. Astrocytes respond 
to this insult with onset of cellular reactivity, which is 
particularly prominent in MS and ultimately leads to 
the formation of chronic lesions [7,8]. IGF is essential 
for proper CNS development and a potent stimulator 
of myelin synthesis and, therefore, possesses thera-
peutic potential for remyelination strategies in MS. 
However, due to its mitogenic capacity on astrocytes, 
treatment based on enhancing IGF-1 signaling could 
augment the process of astrogliosis and further exac-
erbate astrogliotic scaring, a mechanism which is 
thought to impede remyelination processes. Investiga-
tions in our laboratories have demonstrated a defi-
ciency of the β2AR on astrocytes in lesions and normal 
appearing white matter of MS patients, whereas these 
receptors were present on neurons [9]. Astrocytic 
β2ARs are known to engage in a variety of cellular 
functions, such as regulation of immune-inflammatory 
responses, glutamate uptake, and energy metabolism 
[10-13]. Many of these functions operate via the Gsα - Int. J. Med. Sci. 2008, 5 
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adenylyl cyclase pathway, which enhances cAMP, 
leading to PKA activation and further phosphorylation 
of down stream targets. Because of the importance of 
both the β2 adrenergic and type 1 IGF receptor signal-
ing in CNS and the potential role of a deficit of the 
β2AR on astrocytes in MS lesions, we investigated the 
influence of IGF-1, a known modulator of β2AR func-
tions and a potential candidate for therapeutic pur-
poses in MS, on cAMP production in astrocytes de-
rived from mice deficient in β2ARs.  
Materials and methods 
Materials 
Tissue culture plasticware was obtained from 
Nalge Nunc International (Roskilde, Denmark). All 
other cell culture materials were purchased from Gibco 
BRL (UK). For immunohistochemistry, primary anti-
bodies used were rabbit anti-GFAP (Sigma; St Louis, 
MO, USA) and mouse anti-S-100β (Swant, Bellinzona, 
Switzerland). Secondary antibodies for immunofluo-
rescent stainings were, Alexa-fluor 488 
goat-anti-mouse-IgG (FITC-conjugated) and Al-
exa-fluor 568-goat-anti-rabbit (TRITC-conjugated) 
(Sigma). Anti-fading fluorescent mounting medium 
was from DAKO (Ca., USA). Human recombinant 
IGF-1 and NE were purchased from Sigma.  
Generation of Knockout Mice 
Mice lacking functional β2-adrenergic receptors 
have been generated previously and the strategy for 
disrupting this gene has been described [14]. The 
β2AR-deficient mouse (β2AR -/-) was generated by 
homologous recombination resulting in the insertion 
of a neomycin resistance gene cassette into the fourth 
transmembrane domain of the β2-AR gene. These mice 
are viable, fertile and showed no overt phenotypic 
abnormalities. All mice were maintained under speci-
fied pathogen-free conditions and animal studies were 
in accordance with the University and government 
authority’s guidelines. Using PCR techniques, mRNA 
for the β2AR gene could be detected in β2AR +/+, but 
was absent in β2AR -/- mice astrocytes (data not 
shown).  
Cell cultures 
Astrocyte cultures from wild-type (WT) and 
β2AR knockout (KO) mice were prepared according to 
a shake-off protocol described previously [15]. Cere-
bral hemispheres of 1 day-old mouse pups were freed 
from the meninges and mechanically disrupted using a 
Pasteur pipette. After centrifugation (10 min, 300*g) 
single cell suspensions were transferred to culture 
flasks (1 brain/flask) and cultivated for 5 days in 
growth medium (DMEM containing; 10% FCS, 5 
μg/ml pyruvate, 2 mmol/l glutamine, 50 U/ml peni-
cillin, and 50 μg/ml streptomycin and 1000mg glu-
cose/liter). Growth medium was replaced with fresh 
medium twice a week. 7 to 12 days after plating, O2A 
precursor cells and microglia were removed by shak-
ing-off overnight at 250 rpm and 37°C. Two shake-off 
procedures were performed followed by trypsinisation 
of the astrocytic monolayer. The suspended cells were 
filtrated through 100 µm mesh nylon membranes, 
centrifuged (300*g, 15 min), counted and plated into 
poly-L-lysine- (PLL)-coated culture 10cm2 dishes 
(1,000,000 cells/dish) or 12-well multiwell dishes 
(50,000 cells/well), for mRNA isolation or immuno-
cytochemistry, respectively. 2 h after plating, growth 
medium was removed and cells rinsed with phosphate 
buffered saline (PBS) followed by addition of a 
chemically-defined, insulin-free medium (CDM: 
DMEM containing 5 μg/ml pyruvate, 2 mmol/l 
glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, 
5 μg/ml transferrin, and 5 ng/ml selenite) or supple-
mented with 10% FCS for further cultivation. Purity of 
cultures were examined by staining with the astrocytic 
markers S-100β and found to be more than 95% pure 
(data not shown). 
cAMP assay 
Astrocytes were cultured in 96-well plates at a 
density of 20,000 cells / well, incubated in CDM for 48 
hrs and treated with IGF-1 (100ng/ml) or NE (10-5M) 
prior to cell lysis. The cAMP Biotrak competitive en-
zyme immunoassay system kit from Amersham Bio-
science (Buckinghamshire, UK) was utilized for cAMP 
measurement and applied according to manufacturer’s 
suggestions. Samples were subjected to cAMP extrac-
tion and incubated with anti-cAMP antiserum, which 
was immobilized onto secondary antibody pre-
coated-microplates. Peroxidase-labelled cAMP conju-
gate was applied for assay competition. Following 
substrate conversion, absorption was spectropho-
tometrically measured at 450nm. A cAMP standard 
was provided for quantitative calculation of cAMP 
concentrations of astrocyte samples per well. 
Statistical analysis 
All experiments were performed a minimum of 3 
times each, in triplet. For any given experiment, each 
data bar represents the mean +/- SEM of values ob-
tained in separate experiments. Statistical significance 
was determined by one-way Anova analysis. Values of 
P<0.05 were considered significant.  
Results 
Previous examination of isolated astrocyte cul-
tures by light microscopy revealed contrasting prop-
erties regarding proliferation rates of astrocytes de-Int. J. Med. Sci. 2008, 5 
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rived from WT mice, as compared to those derived 
from mice with a β2AR deletion. While cell morphol-
ogy remained unaltered, KO astrocytes grew more 
rapidly, a characteristic which was visible and quanti-
fiable after 3 days in culture [16].   
The effects of cAMP on cell proliferation and dif-
ferentiation are well documented and was our motive 
for evaluation of cAMP levels in WT and KO astro-
cytes. In untreated cells, basal cAMP levels demon-
strated 47.3% lower concentrations in KO astrocytes as 
compared to WT cells (p<0.05; figure 1). NE, a 
non-specific agonist which interacts with both alpha- 
and beta-adrenergic receptor sites and generally 
regulates cAMP concentrations. Treatment of astro-
cytes with NE (10-5M) for 15 minutes, prior to har-
vesting of cell lysates, resulted in enhanced levels of 
cAMP in both WT and KO cells by 115% and 135.3%, 
as compared to untreated cells, respectively. Despite 
the absence of β2ARs in KO cells, NE increased cAMP 
levels, which is likely a result of stimulation of other 
adrenergic receptors that signal via Gs and activate 
adenylyl cyclase. NE-induced increase in cAMP pro-
duction reached a maximum after 15-minute treatment 
and declined after a 30-minute exposure to NE in both 
WT  an d K O  c el ls . I n  res p o n se t o  I G F -1  ( 5 0n g/ m l ;  1  
minute treatment), cAMP levels were reduced in WT 
cells by 50% and remained reduced after a 30-minute 
exposure to IGF-1 (figure 1; p<0.05, as compared to 
untreated WT cells). β2AR deficient astrocytes demon-
strated no changes in cAMP levels in response to IGF-1 
treatment.  
 
 
Figure 1: Intracellular cAMP levels in astrocytes. Astrocytes 
were plated in 96-well plates (20,000 cells/well) and cultivated 
in CDM containing 0% FCS. Basal levels of untreated cells 
demonstrate 47.3% lower cAMP levels in KO astrocytes, as 
compared to WT cells. Treatment with NE for 15 minutes in-
creased cAMP levels in both WT and KO astrocytes by 115.1% 
and 135.3%, respectively. NE-induced cAMP concentration 
was reduced in both WT and KO after 30 minutes treatment. 
Treatment with IGF-1 for 1 minute reduced cAMP levels by 
50% in WT cells only, an effect that was still observed after 5, 
10 and 30 minute treatments. β2AR deficient astrocytes dem-
onstrated no changes in cAMP levels in response to IGF-1 
treatment. Data represents mean +SEM. *, p<0.05 compared to 
untreated WT cells; #, p<0.05 compared to untreated KO cells.  
 
Discussion 
cAMP is involved in cellular prolifera-
tion-differentiation processes as demonstrated on as-
trocytes with dibutyryl cAMP (dBcAMP), which initi-
ates a more differentiated status of astrocyte with re-
duced proliferative capacity [17]. dBcAMP has also 
been shown to inhibit IGF-1-induced mitogenesis in 
cells by inhibiting Raf-1 kinase activity, an effect that 
has been attributed to phosphorylation of Raf-1 by 
protein kinase A [17-19]. Interestingly, we have shown 
that cultured β2AR KO astrocytes, which proliferate 
more rapidly than wild type cells [16], display reduced 
basal cAMP levels. This reduction in basal cAMP in 
β2AR deficient cells might be accounted for by the ab-
sence of constitutive activity, which is known for the 
β2AR. In addition to agonist-induced activation, β2AR 
can undergo spontaneous conformational changes, 
resulting in ligand-independent activation [20].   
In addition to Gs activation and consequent 
cAMP production, the β2AR can activate Gi proteins, a 
property that is unique amongst the beta-adrenergic 
receptors. Activation of Gi results in enhanced sur-
v i v a l ,  a n  e f f e c t  w h i c h  i s  t h o u g h t  t o  b e  m e d i a t e d  b y  
elevated activity of Akt/PKB [21]. An absence of β2AR 
signaling in astrocytes and consequent reduction of 
Akt/PKB activation might be compensated by in-
creased IGF signaling as demonstrated previously [16]. 
This compensatory mechanism might explain en-
hanced astrocytic proliferation.   
We have demonstrated that treatment with IGF-1 
reduced cAMP levels in WT astrocytes, yet had no 
effect on KO cells. Although IGF-1 had a clear effect on 
cAMP production in WT cells, the mechanism by 
which IGF receptor signaling is involved in this regu-
lation is uncertain. As mentioned above, IGF-1 can 
catalyze the phosphorylation of the β2AR, which re-
sults in loss of function of this receptor and inhibition 
of adenylyl cyclase Gs activation [6,22]. Although we 
demonstrate that IGF-1 has the potential to regulate 
cAMP levels in astrocytes in a β2AR-dependent man-
ner, we do not know whether this occurs through di-
rect phosphorylation and subsequent desensitization 
of the β2AR by the IGF-1R, a notion which remains 
speculative.  
We have previously reported a loss of β2AR on 
astrocytes in cerebral white matter of patients with MS, Int. J. Med. Sci. 2008, 5 
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a deficit which may contribute to pathology of this 
disease by several possible mechanisms such as im-
paired astrocytic glycogenolysis. Insufficient glyco-
genolysis could decrease energy supplies to axons and 
may contribute to axonal degeneration [23]. In this 
context, cAMP physiological effects include crucial 
roles in regulating energy metabolism, such as lipoly-
sis, gluconeogenesis, and glycogenolysis [24]. Loss of 
β2AR on astrocytes in MS might also contribute to en-
hanced astrogliosis and cellular reactivity, a hallmark 
trait in MS lesions. Regulation of cell growth by the 
β2AR, a receptor which is involved in processes of 
proliferation and differentiation, has been implicated 
in astrocytes in vitro [16].   
In summary, β2AR deficient astrocytes have 
lower basal cAMP levels as compared to wild type 
cells. This reduction of cAMP levels may be involved 
in the increased cell proliferation as reported previ-
ously. We show here that stimulation with IGF-1 re-
duces cAMP levels in astrocytes in a β2AR-dependent 
manner, a reduction of which may promote some of 
the mitogenic properties of IGF signaling.  
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